Dare Bioscience, Inc. current report, 15 August 2017

Business Context and Reporting Period

This Form 8-K Current Report was filed by Dare Bioscience, Inc. on August 15, 2017. The filing discloses the execution of new employment agreements with three key members of management, effective retroactively as of July 19, 2017.

Key Financial Metrics

This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation arrangements.

Executive Title Annual Base Salary Target Bonus % One-Time Payment
Sabrina Martucci Johnson President and CEO $325,000 50% $0
Lisa Walters-Hoffert Chief Financial Officer $260,000 35% $45,500
Mark Walters Vice President of Operations $220,000 30% $33,000

Material Changes

The primary material change is the formalization of compensation terms for the CEO, CFO, and VP of Operations. These agreements establish fixed base salaries, performance-based bonus structures, and specific severance provisions that were not previously detailed in this manner.

Outlook, Risks, and Unusual Items

Severance and Change of Control Provisions:

  • CEO (Ms. Johnson): Entitled to 12 months of base salary plus accrued bonus and health benefits upon termination without cause or for good reason. In the event of a change of control, this increases to 18 months of base salary and target bonus, with full acceleration of unvested equity.
  • CFO (Ms. Walters-Hoffert): Entitled to 9 months of base salary plus accrued bonus and health benefits upon termination without cause or for good reason. In the event of a change of control, this increases to 12 months of base salary and target bonus, with full acceleration of unvested equity.
  • VP Operations (Mr. Walters): Entitled to 6 months of base salary plus accrued bonus and health benefits upon termination without cause or for good reason. In the event of a change of control, this increases to 9 months of base salary and target bonus, with full acceleration of unvested equity.

Contract Terms: All agreements have an initial two-year term with automatic one-year renewals unless terminated with 60 days' notice. Employees may terminate for "good reason" after a 14-day cure period.

Investor Verification Checklist

  • Verify the total cash outflow for the one-time payments ($78,500 total) and the impact on the company's current cash position.
  • Review the full text of Exhibits 10.1, 10.2, and 10.3 to understand specific definitions of "good reason" and "cause."
  • Assess the potential liability exposure regarding the change of control acceleration clauses for unvested equity.
  • Confirm the company's ability to fund the potential severance packages (ranging from 6 to 18 months of salary) in a liquidity-constrained scenario.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.